NCT03175887

Investigational TMS Treatment for Depression

Dorsolateral Versus Medial Prefrontal TMS for Depression

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: White River Junction Veterans Affairs Medical Center · Federal
• Sex: All
• Age: 21 Years – 70 Years
• Healthy volunteers: Accepted

Summary

This study is aimed to help us learn about the effects of Transcranial Magnetic Stimulation at the forehead versus the left side of the head for treatment of Treatment Resistant Depression.

Detailed description

While transcranial magnetic stimulation (TMS) to the left dorsolateral prefrontal cortex (DLPFC) is an FDA approved treatment for depression, a growing and converging database suggests the medial prefrontal cortex (MPFC) may be even more critical to the neurobiology of depression and antidepressant treatment response. This study will compare the efficacy of high frequency transcranial madntic stimulation on these two sections of the brain.

Conditions

• Depression
• Treatment Resistant Depression

Interventions

Type	Name	Description
DEVICE	TMS	Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression.

Timeline

• Start date: 2021-09-01
• Primary completion: 2022-08-01
• Completion: 2022-09-01
• First posted: 2017-06-05
• Last updated: 2021-05-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study